Application of recombinant SPRR2A protein screened based on transcriptome in preparation of high-energy neutron radiation intestinal injury repair agent

Sprr2a was identified as a biomarker for intestinal damage caused by high-energy neutron radiation through transcriptome screening. Recombinant SPRR2A protein was prepared for high-energy neutron radiation protection, which solved the problem of poor efficacy of existing protective agents and achieved the repair and protection of intestinal damage, thus having important application value.

CN122398997APending Publication Date: 2026-07-17THE NAVAL MEDICAL UNIV OF PLA
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-10
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing protective agents are not very effective against intestinal damage caused by high-energy neutron radiation, especially intestinal barrier disruption and crypt damage, and there is a lack of safe and effective protective measures.

Method used

Recombinant SPRR2A protein, selected based on transcriptome screening, was used as a repair agent for intestinal damage caused by high-energy neutron radiation. It promoted the proliferation of intestinal crypt cells and enhanced the activity of intestinal stem cells. The specific mechanism included upregulating the expression of Lgr5, Olfm4 and Ascl2 genes.

Benefits of technology

It significantly reduces villus atrophy and crypt structure damage in the mouse intestine after high-energy neutron radiation, restores intestinal mucosal barrier function, and enhances the ability of intestinal crypts to form organoids, providing a novel biological agent for nuclear accident emergency medical rescue, tumor radiotherapy protection, and aerospace medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122398997A_ABST
    Figure CN122398997A_ABST
Patent Text Reader

Abstract

The application discloses application of recombinant SPRR2A protein based on transcriptome screening in preparation of a high-energy neutron radiation intestinal injury repair agent, identifies, for the first time, a small proline-rich protein family member Sprr2a as a specific sensitive marker for high-energy neutron radiation intestinal injury, and for the first time, applies the recombinant SPRR2A protein to high-energy neutron radiation protection. The recombinant SPRR2A protein can promote intestinal crypt cell proliferation and / or improve intestinal stem cell activity, improve the ability of intestinal crypts to form organoids after high-energy neutron radiation, solve the technical bottleneck that existing protection agents have poor high-LET radiation protection effect, and have important application value in the fields of nuclear accident emergency medical rescue, tumor radiotherapy, space medicine and the like.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Application of PARP1 inhibitor in preparation of radiation damage repair medicine

    CN118512594A